Learn more about investing in Laguna Bio

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
Laguna Bio
The newest cancer killers on the block
Funding to Date*
* Data source: Crunchbase
CEO Jonathan Kotula, PhD
"γδ T cells can uniquely generate robust and durable cytotoxicity against cancer and nothing produces more (gamma delta) T cells than Laguna Listeria."
2 out of 3 patients with solid tumors don’t experience a robust anti-tumor response, even with cutting-edge cancer therapies

Laguna Bio is perfecting an entirely new approach to selectively activate and expand a specific type of T cell, the gamma-delta T (γδ T) cells, to take full advantage of the immune system’s ability to fight solid tumors. The γδ T cells are an obscure but homogeneous population of immune cells that you can count on to kill cancer cells. CAR-γδ T cells have shown success in clinical studies of B-cell lymphoma; Allogeneic γδ T cells have already shown promise in liver and lung cancers.

Building on a collaborator’s positive human data and from live-attenuated Listeria, Laguna is designing a proprietary Listeria to be the safest and most robust yet highly selective activator of these T cells. Increasing response rate of a bispecific antibody drug using Laguna’s listeria would be a major advance for those with solid tumors and represents a multi-billion dollar opportunity.